Soluble Biomarker Analyses
Thanks to our broad assortment of assay platforms, you can be assured the biomarker specialists at ABL have solutions for even your most difficult analyte challenges.
The remarkable advances in immunotherapy are facing unexpected challenges in predicting which patient populations will benefit from treatment, develop immune-related adverse events or relapse. In the era of personalized medicine, it has become a top priority to identify and characterize factors that will allow early diagnosis and therapeutic intervention in pathologies such as cancer, autoimmune or inflammatory diseases and neurodegenerative disorders.
Multiplexing technologies such as Luminex, MSD, or ultra-sensitive platforms, such as the SIMOA™ (Quanterix) or Cira™ (Aushon), offer deeper characterization of the complexity and dynamics of circulating biomarkers early in disease acquisition and progression.
As experts in immunoassay development and validation, ABL offers:
- Expert advice on the most relevant biomarkers and detection methods
- Assay development, optimization and fit-for-purpose analytical validation
- Sample testing for both preclinical and clinical studies
Examples of Biomarkers Assessed at ABL
The table below is a non-exhaustive list to be used only as an example of our capabilities. Our only limitations are the vendors’ catalogs, which are extremely large and constantly growing.